The role of initial coping strategies on subsequent appointment attendance in individuals with HIV:  a longitudinal analysis by Johnson, DeAnn Morris
Louisiana State University
LSU Digital Commons
LSU Doctoral Dissertations Graduate School
2002
The role of initial coping strategies on subsequent
appointment attendance in individuals with HIV: a
longitudinal analysis
DeAnn Morris Johnson
Louisiana State University and Agricultural and Mechanical College
Follow this and additional works at: https://digitalcommons.lsu.edu/gradschool_dissertations
Part of the Psychology Commons
This Dissertation is brought to you for free and open access by the Graduate School at LSU Digital Commons. It has been accepted for inclusion in
LSU Doctoral Dissertations by an authorized graduate school editor of LSU Digital Commons. For more information, please contactgradetd@lsu.edu.
Recommended Citation
Johnson, DeAnn Morris, "The role of initial coping strategies on subsequent appointment attendance in individuals with HIV: a
longitudinal analysis" (2002). LSU Doctoral Dissertations. 1013.
https://digitalcommons.lsu.edu/gradschool_dissertations/1013
  
THE ROLE OF INITIAL COPING STRATEGIES ON SUBSEQUENT 
APPOINTMENT ATTENDANCE IN INDIVIDUALS WITH HIV: 
A LONGITUDINAL ANALYSIS 
 
 
 
A Dissertation  
 
Submitted to the Graduate Faculty of the  
Louisiana State University and 
Agricultural and Mechanical College 
in partial fulfillment of the  
requirements for the degree of 
Doctor of Philosophy 
in  
The Department of Psychology 
 
 
 
 
by  
DeAnn Morris Johnson 
B.A. Southeastern Louisiana University, 1995 
M.A. Southeastern Louisiana University, 1997 
May, 2002 
 
 
 ii 
Acknowledgements 
As with any worthwhile endeavor, the current project could not have been completed 
without support and guidance from many individuals.  I would like to thank Mike Hawkins, 
Ph.D., Phillip Brantley, PhD., Amy Copeland, Ph.D., and Maren Hegsted, Ph.D. for their 
valuable input and efforts in improving this project.   
In addition I would like to express my great appreciation to Wm. Drew Gouvier, Ph.D., 
my mentor, who has guided my professional development and has frequently gone above and 
beyond the call of duty to help out when needed.  
Without Glenn Jones, Ph.D. this project would have been impossible to complete.  Thank 
you for all of the help with the constant struggle to collect data.  I would also like to express my 
appreciation to Stephanie Knoll and Jamie Bolin for their efforts in data collection. 
Finally, a very special thanks goes to my family.  Thank you to Mom, Dad, Scott, Little 
Maw Maw, Big Maw Maw, and Paw Paw.  Their years of unwavering love, support, and 
patience have made pursuing my dream of a career in clinical psychology possible.  To my 
husband, Jack Johnson, go incredible thanks and lots of love for his steadfast belief in my ability 
to reach my goals and for always being able to make me laugh. 
 
 
 
 
 
 iii 
Table of Contents 
Acknowledgements................................................................................................................... ii 
List of Tables ........................................................................................................................... iii 
Abstract ......................................................................................................................................v 
Introduction................................................................................................................................1 
       Adherence ...........................................................................................................................4 
                Adherence in Chronic Illness.....................................................................................5  
       Adherence in persons with HIV..........................................................................................6 
                HIV Treatment Characteristics ..................................................................................6 
                Individual Characteristics ..........................................................................................7  
            Depressive Symptoms........................................................................................8 
                        Substance Abuse................................................................................................8 
       Coping.................................................................................................................................9 
                The Impact of Coping on Adherence.......................................................................11  
       Limitations in the Current Adherence Literature..............................................................12 
       Summary ...........................................................................................................................13          
Methods....................................................................................................................................17 
       Participants........................................................................................................................17 
       Measures ...........................................................................................................................17 
                Demographic Questionnaire ....................................................................................17 
                Appointment Adherence..........................................................................................18 
                Ways of Coping Questionnaire Adapted for HIV ...................................................18 
                Center for Epidemiological Studies Depression Scale ............................................20 
                Substance Abuse......................................................................................................20 
                Illness Severity.........................................................................................................20 
       Procedure ..........................................................................................................................21  
                Research Design ......................................................................................................22 
Results......................................................................................................................................23 
       Analysis of Demographic Data.........................................................................................23 
       Analysis of Total Attendance ...........................................................................................27 
       Analysis of Coping and Attendance .................................................................................28 
       Analysis of Attenders and Nonattenders on an Annual Basis ..........................................30 
                Analysis of Attenders vs. Nonattenders by Ethnicity..............................................31 
                Analysis of Attenders vs. Nonattenders by Gender.................................................32 
                Analysis of Attenders vs. Nonattenders by Sexual Orientation ..............................33 
                Analysis of Attenders vs. Nonattenders by Intravenous Drug Use History ............34 
                Analysis of Attenders vs. Nonattenders by Current Substance Abuse....................35 
       Analysis of Attrition Related Variables............................................................................36 
Discussion................................................................................................................................39 
       Appointment Attendance ..................................................................................................39 
 iv 
                Ethnicity and Appointment Attendance...................................................................39 
                Depressive Symptoms and Appointment Attendance..............................................40 
                Intravenous Drug Use and Appointment Attendance ..............................................42 
       Coping...............................................................................................................................42 
                Coping and Appointment Attendance......................................................................42 
                Coping and Ethnicity ...............................................................................................44 
                Relationship Between Coping and Depressive Symptoms......................................45 
                Substance Use and Coping.......................................................................................45 
       Summary ...........................................................................................................................46 
References................................................................................................................................48 
Appendix A: Demographics Questionnaire .............................................................................56 
Appendix B: Ways of Coping Questionnaire Subscales..........................................................57 
Appendix C: Symptom Checklist for HIV Infection ...............................................................58 
Appendix D: Informed Consent...............................................................................................59 
Vita...........................................................................................................................................61 
 iv 
List of Tables 
1. Sample Comparison: Demographic Characteristics ....................................................24 
2. Descriptive Statistics: Study Completers.....................................................................25 
3. Correlation Matrix: Demographic and Medical Variables ..........................................26 
4. Correlation Matrix:  Intercorrelations among WCQ Scales ........................................26 
5. Multiple Regression Analysis: Coping and Appointment Attendance ........................30 
6. Year One: Chi Square Test of Independence for Attendance: Ethnicity .....................32 
7. Year Two: Chi Square Test of Independence for Attendance: Ethnicity ....................32 
8. Year Three: Chi Square Test of Independence for Attendance: Ethnicity ..................32 
9. Year One: Chi Square Test of Independence for Attendance: Gender........................32 
10. Year Two: Chi Square Test of Independence for Attendance: Gender .......................33 
11. Year Three: Chi Square Test of Independence for Attendance: Gender .....................33 
12. Year One: Chi Square Test of Independence for Attendance: Orientation .................33 
13. Year Two: Chi Square Test of Independence for Attendance: Orientation.................34 
14. Year Three: Chi Square Test of Independence for Attendance: Orientation...............34 
15. Year One: Chi Square Test of Independence for Attendance: IV Drug Use ...............34 
16. Year Two: Chi Square Test of Independence for Attendance: IV Drug Use ..............35 
17. Year Three: Chi Square Test of Independence for Attendance: IV Drug Use ............35 
18. Year One: Chi Square Test of Independence for Attendance: Substance Use ............35 
19. Year Two: Chi Square Test of Independence for Attendance: Substance Use............36 
20. Percentage of Sample Attrition by Study Year............................................................36 
21. Multiple Regression Analysis: Lost to Follow Up ......................................................38  
 v 
Abstract 
  With advances in HIV treatment regimens, HIV has become a treatable chronic illness 
that requires extensive clinical management (Kelly, Otto-Salaj, Sikkema, Pinkerton, & Bloom, 
1998).  Nonadherence to HIV medical regimens is a primary reason for treatment failure.  HIV 
medication regimens are complicated and require extensive time and effort from the patient 
(Friedland & Williams, 1999).  Since the effectiveness of HIV medication regimens can be severely 
limited by poor adherence, much research has been conducted regarding the influence of 
psychosocial factors in adherence. However, this research has primarily focused on medication 
adherence and has not investigated psychosocial aspects associated with other adherence related 
behaviors such as appointment attendance. Thus, the current literature may be missing an entire 
group of HIV patients who do not follow through with medical care long enough to receive 
medications or other available treatments and services.   
 The primary purpose of this study was to evaluate the effects of initial coping strategies 
on long-term appointment attendance in individuals with HIV.  Baseline data collection was 
conducted between 1992 and 1995 and included information concerning demographic factors, 
illness severity, depressive symptoms, and coping strategies.  The current results were obtained 
by a retrospective chart review of appointment attendance.  It was predicted that problem-
focused coping would be associated with attending regularly scheduled clinic visits and emotion-
focused coping would be predictive of failure to attend appointments. Multiple regression 
analysis revealed that the coping style employed by participants did not predict appointment 
attendance above and beyond the variance predicted by demographic, illness, and distress related 
factors.  However, minority status, depressive symptoms, and history of intravenous drug use did 
emerge as reliable predictors of failure to attend scheduled clinic appointments over a three-year 
follow-up period.  These results suggest that increased depressive symptoms, a history of 
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intravenous drug use, and being African American negatively impact treatment success by reducing 
appointment attendance.  Further research should evaluate the specific variables associated with 
poor appointment attendance among minority individuals. 
 1 
Introduction 
      The Human Immunodeficiency Virus (HIV), which leads to Acquired Immunodeficiency 
Syndrome (AIDS), has become a worldwide health threat.  HIV disease strikes the immune 
system and slowly degrades the body’s ability to ward off infections and other illnesses.  
Approximately 47 million people have been infected with HIV worldwide (Fan, Connor, & 
Villarreal, 2000). Currently, there are about 400,000 people living with HIV or AIDS in the 
United States (Center for Disease Control and Prevention [CDC], 1999).  Although AIDS-related 
deaths are declining, the number of people living with HIV or AIDS continues to increase.  
Between 1997 and 1998, there was a ten percent rise in the number of new HIV infections (CDC, 
1999).  According to the CDC (1999), minorities are disproportionately represented in this 
population. Minorities, particularly African Americans, account for 80% of the women and 61% 
of the men with HIV.  This trend appears to be continuing and emphasizes the importance of 
research aimed at effective psychosocial treatments of this rapidly growing population.   
 HIV is most commonly transmitted through sexual contact and sharing of contaminated 
needles.  Intravenous drug use is the second highest risk factor for contracting HIV infection 
(CDC, 1999; Chitwood, et al., 2000).  However, non-intravenous substance use such as crack 
cocaine and alcohol also increase the risk of engaging in unsafe sexual behaviors that may 
increase exposure to HIV (Stall, McKusick, Wiley, Coates, & Ostrow, 1986).  HIV can also be 
transmitted from mother to child during pregnancy, birth, or lactation.  Although quite rare, HIV 
can be transmitted to healthcare workers through accidental needle sticks.   
HIV belongs to a class of viruses called retroviruses.  Retroviruses encode their genetic 
information in RNA rather than DNA and have a complex life cycle.  Retroviruses consist of 
three main components including a group of core particle proteins, the enzyme reverse 
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transcriptase, and a protein coat.  Reverse transcriptase allows the virus to replicate and the 
protein coat helps the virus bind with other cellular receptors (Fan, et al., 2000).  During the 
initial infection process, the genetic RNA core of the retrovirus binds with the receptors of 
uninfected cells and invades the host cells.  Next, reverse transcriptase converts RNA into viral 
DNA and is integrated into the cellular machinery.  This allows the infected cell, or virion, to 
continue functioning normally and the virus to replicate rapidly (Fauci, 1988).   
     The principle target cell of HIV is T lymphocytes, or T-cells.  T-cells contain CD4 
protein receptor sites which assist other immune system cells in eliminating foreign particles or 
pathogens from the body.  HIV binds with these CD4 receptors, thus killing T-cells.  As T-cells 
are destroyed, immune system functioning declines and infectious agents are not eliminated from 
the body.  Consequently, illnesses or infections that would rarely survive in the body of a healthy 
individual to develop, proliferate, and ultimately lead to the death the infected individual. 
  The CDC has defined four primary stages of HIV infection. The progression of these 
stages varies across individuals.  The first phase is an acute HIV syndrome that is sometimes 
called seroconversion illness.  Individuals may experience vague flu-like symptoms including 
fever, fatigue, rash and enlarged lymph nodes.  Because these symptoms are nonspecific, people 
rarely seek medical attention at this point.  The second stage is commonly referred to as the silent 
phase and includes a prolonged asymptomatic period that usually lasts between five and ten 
years.  During the silent stage there is a progressive build-up of the virus in the body (particularly 
in the lymph nodes, spleen, and liver) with a concurrent drop in T-cells.  The third stage of HIV 
infection, the symptomatic phase, is characterized by the presence of noticeable symptoms. 
These symptoms include enlarged lymph nodes in the head and neck region, persistent low-grade 
fever, night sweats, chronic diarrhea, peripheral neuropathy, and oral ulcers. On average, the 
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symptomatic phase lasts approximately three years until an AIDS diagnosis is made.  The fourth 
stage, AIDS, is marked by the presence of opportunistic infections or cancers (e.g., Kaposi’s 
sarcoma) and a T-cell count below 200 cells per cubic millimeter.  Without intervention, 
opportunistic infections and other illnesses eventually lead to death.  However, recent advances 
in treatment have dramatically lengthened the symptomatic phase and delayed the onset of AIDS 
and eventual death (Kelly, Ott-Salaj, Sikkema, Pinkerton, & Bloom, 1998).   
Initially, treatment of HIV/AIDS was limited to the clinical management of the opportunistic 
infections that result from HIV infection (Kelly et al., 1998).  In the mid 1980's drugs called 
nucleoside analogues, such as zidovudine (AZT), were introduced as the first successful 
treatment for HIV infection.  AZT and other similar drugs (e.g. didanosine, lamivudine) limit the 
ability of HIV to produce DNA and thereby decreased the rate of HIV cell replication (Fan et al., 
2000).   Although individuals who received these medications experienced some side effects 
(headache, nausea, insomnia) they also had fewer opportunistic infections, increased T- cell 
counts, and improved survival rates when compared to untreated individuals at a similar stage of 
illness (Volberding, et al., 1994).   
      Between late 1995 and early 1997 a new class of antiretroviral medications called 
protease inhibitors was introduced.  These drugs prevent the production of HIV by directly 
inhibiting the enzyme (protease) responsible for viral maturation, thus slowing the replication of 
HIV.   Treatment regimens that combine protease inhibitors with at least two other nucleoside 
analogues (i.e., combination therapy) have been associated with increased T-cell counts, 
decreased levels of HIV circulating in the blood (i.e., viral load), improved health outcomes, and 
life extension (Deeks, Smith, Holodniy, & Kahn, 1997; Nelson, 1996).   As with the initial 
treatments for HIV, the benefits of combination therapy are often limited by side effects.  Many 
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side effects including fatigue, insomnia, diarrhea, gastro-intestinal discomfort, nausea, and 
vomiting are transient and tend to subside within one to two months (Lin-in Tseng, 1998).  
However, other side effects such as oral numbness and peripheral neuropathy are more long 
lasting and often require medical intervention (Lin-in Tseng, 1998).  The success of combination 
therapy has also been limited by the complicated nature of the medication regimens. These 
regimens require significant time and effort from patients in order to be successful (Carpenter et 
al, 2000).   
      HIV medications must be taken on a demanding schedule and require frequent physician 
visits to monitor the patient’s progress and prevent complications. Individuals who are less 
adherent with their treatment regimens do not fully benefit from treatment and experience more 
opportunistic infections (Montaner et al., 1998; Friedland & Williams, 1999).  Although 
adherence has been an important factor in chronic illness research in the past, complex HIV 
treatments have generated resurgence in this research 
Adherence 
 The importance of adherence in medical regimens is not a new concept.  About 25 
years ago researchers began to investigate the factors associated with carrying out medical 
instructions (Haynes, 1976).  Haynes defined medical compliance as the “extent to which a 
person’s behavior coincides with medical or health advice” (Haynes, 1976).  Presently, the term, 
compliance, has fallen out of favor and has been replaced with the term adherence.  Instead of 
portraying the person as a passive recipient who complies with medical advice, the term 
adherence denotes the collaborative, interactional nature of the relationship between individuals 
and medical professionals (Turk, Salovey, & Litt, 1986).  This definition of adherence 
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encompasses a broad array of behaviors including medication intake, appointment attendance 
and other health related behaviors.  
Adherence in Chronic Illness 
 Adherence to medical regimens has been studied in a variety of chronic medical 
conditions including diabetes, coronary artery disease, and tuberculosis (Epstein, 1984; Friedland 
& Williams, 1999; Horowitz et al., 1990; O’Brien, Petrie, & Raeburn, 1992).  Adherence rates 
among patients with chronic illnesses are surprisingly low and even under ideal conditions rarely 
reach 100 percent.  It has been estimated that 30% to 60% of patients do not take medications as 
prescribed (Augenbraum, et al., 1998; Cramer, Mattson, Prevey, Scheyer, & Oulette, 1989; 
Dunbar-Jacobs, Dwyer, & Dunning, 1991).  Adherence rates are also low when other health 
related behaviors are considered.  For example, Gerber (1986) reported that medical 
appointments are missed as much as half of the time.  
 Research has not identified a single variable or group of variables that can reliably predict 
who will be adherent with treatment regimens; however, many variables have been linked to 
adherence. In general, patient characteristics such as age, gender, ethnicity, and educational 
levels have not been shown to be good predictors of adherence, (Besch, 1995; Griffith, 1990; 
Meichenbaum & Turk, 1987).  However, the most reliable adherence occurs when the illness in 
question is short term, and produces obvious disease symptoms (O’Brien, et al., 1992).  
Consequently, decreased medication adherence has been associated with complex and long-
lasting medical regimens that include multiple medications and frequent drug administration, 
such as HIV treatments (Griffith, 1990).  
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Adherence in Persons with HIV 
 Research has documented substantial rates of non-adherence with HIV medication 
regimens, even during brief periods of time.  Early studies of monotherapy estimated that 
successful adherence (taking at least 80% of prescribed doses) only occurred approximately 42% 
of the time when monitored over the previous month (Singh et al, 1996) and 67% of the time 
when monitored over the previous week (Samet et al., 1992).  Similar results have been noted 
studies of adherence to combination regimens.  Hecht, Colfax, Swanson, & Chesney (1998) 
found that outpatients at an AIDS clinic in San Francisco reported missing 20 percent or more of 
their HIV medications over a short three-day period. This is consistent with other results 
regarding combination therapy including a study by Catz and colleagues that found that one third 
of patients reported missing medication doses within the past five days (Catz, Kelly, Bogart, 
Benotsch, & McAuliffe, 2000).  Because poor treatment adherence represents a major problem 
facing individuals with HIV and substantially impacts the effectiveness of their treatment, much 
research has been conducted to investigate the factors associated with HIV treatment adherence.  
These variables can be divided into two main categories: HIV treatment characteristics and 
individual characteristics.  
HIV Treatment Characteristics 
 In general, research has shown that medical regimens are more likely to be followed 
when the disease is brief, treatment regimens are simple, and the medication removes salient 
symptoms (Agras, 1989; Blackwell, 1992; Nannis, Temoshock, Smith, & Jenkins, 1993).  
Additionally, complicated treatment regimens that involve large numbers of medications with 
difficult dosing requirements and troublesome side effects have been associated with 
nonadherence (Dunbar-Jacobs, et al., 1991).  Because HIV infection is a chronic illness that does 
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not always produce overt symptoms and involves a complex and demanding course of treatment, 
the HIV medication regimens that are currently available have not proven to be representative of 
the ideal conditions to promote adherence (Friedland & Williams, 1999).   
Individual Characteristics 
 HIV medication adherence is best when the individual is educated about the treatment 
(Eldred, Wu, Chaisson, & Moore, 1998; Stall et al., 1996), believes the treatment is needed 
(Blumenfield, Milazzo, & Wormser, 1990), has support from family and friends, (Mostashari, 
Riley, Selwyn, & Altice, 1998; Singh, et al., 1999; Stall et al, 1996), and is convinced of 
treatment efficacy (Catt, Stygall, & Catalan, 1995; Muma, Ross, Parcel, & Pollard, 1995).   
 As with other illnesses, initial research showed that demographic variables such as age, 
gender, and education level were not good predictors of adherence to HIV medication treatments 
(Muma et al., 1995; Singh, et al., 1996).  However, many of these studies included samples that 
consisted of primarily Caucasian homosexual males. Other studies, that have included broad 
samples more representative of the entire population of individuals with HIV, have shown 
demographic factors, particularly ethnicity, are predictive of decreased adherence (Eldred, et al., 
1998; Singh, et al. 1996; Singh et. al, 1999).  For example, Singh and colleagues (1999) found 
that 31% of Caucasians were adherent with medication regimens, but only 12% of minority 
participants (predominately African-American) followed their medication regimens.  
Demographic differences are even stronger when the definition of adherence is broadened to 
include variables such as appointment attendance (Catz, McClure, Jones, & Brantley, 1999;  
Israelski, Gore-Felton, Power, Wood, & Koopman, 2001; Kissinger, 1995; McClure, Catz, & 
Brantley, 1999).  Given the current increased incidence of HIV among the minority population, 
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understanding these ethnic differences and related psychosocial factors is especially important 
(CDC, 1999; CDC, 2000).   
 Other individual variables have been found to negatively impact adherence.  
Psychological difficulties have been associated with decreased appointment attendance, 
particularly when depressive symptoms or substance use is involved (Catz et al., 1999; 
O’Connor, Selwyn, Schottenfeld, 1994).  Each of these factors will be reviewed briefly below.  
Depressive Symptoms:  Individuals with HIV may be at a greater risk for experiencing 
depressive symptoms due to the stressors associated with living with a fatal and stigmatizing 
illness. Depression is a common problem among individuals with HIV.  It is estimated that 20% 
of individuals with HIV/AIDS experience depression (Heckman, Kochman, Sikkema, & 
Kalichman, 1999).  Depression can seriously impact patients overall well-being and adherence to 
their medical regimens.  
 Studies have shown that HIV patients who experience increased depressive symptoms 
demonstrate poor adherence, report more pain, have lower T-cell counts (i.e., indicating greater 
illness), and increased substance use compared to HIV patients with average levels of depressive 
symptoms (Blumenfield, et al., 1990, Bogart, et al., 2000, Catz, et al., 2000; Kalichman, 
Ramachandran, & Catz, 1999; Rabkin,& Ferrando, 1997; van Servellen, Sarna, Padilla, & 
Brecht, 1996.; Vassend & Eskild, 1998).  Furthermore, depression has been linked to poor health 
outcomes in individuals with HIV including increased progression of HIV to AIDS and 
increased mortality (Ironson et al., 1994; Leserman, et. al, 2000; Mayne, Vittinghoff, Chesney, 
Barrett, & Coates, 1996; Page-Schafer, Delorenze, Satariano, & Winkelstein, 1996).     
Substance Abuse: A large number of individuals with HIV who have a history of substance use 
may continue using illicit drugs while receiving treatment for HIV.  Substance abuse may lead to 
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problems with treatment adherence and ultimately treatment failure.  Substance use has been 
linked to poor adherence and may lead to increased viral progression (Dickinson, 1998; 
Haubrich, et al., 1999; O’Connor et al, 1994; Samet et al., 1992).  Eldred and his colleagues 
(1998) found that HIV patients cited problems associated with the use of drugs and alcohol as the 
third most common reason for missing HIV medications.  Substance use is also important in 
adherence behaviors not directly related to medication intake. For example, substance use has 
been consistently identified as a primary risk factor in missed clinic appointments (Kissinger, et 
al., 1995; McClure, et al., 1999).  Consequently, many individuals who have a history of 
substance use may be at risk for dropping out of treatment entirely.  Little research exists that 
help explain the role of substance abuse in adjustment to HIV treatment demands. 
 Coping strategies have been shown to be useful in helping individuals manage the 
psychosocial stressors associated with HIV (Chesney, Folkman, & Chambers, 1996; Siegel, 
Gluhoski & Karus, 1997).  The strategies individuals use to cope with HIV treatment are an 
important mental health issue because these strategies ultimately influence treatment success 
(Kelly et al, 1998).  Recent studies have also shown that the coping strategies individuals use to 
adjust to HIV, may impact their participation in treatment. 
Coping 
 Coping involves cognitive and behavioral efforts to manage problems caused by stressful 
situations.  Lazarus and Folkman (1984) defined coping as a dynamic process based on an 
individual’s appraisal of the extent to which the stressor outweighs their psychological resources.  
Coping includes adaptive efforts to manage the external or environmental aspects of a stressor, 
and avoidant behaviors to minimize exposure to the stressful situation (Lazarus, 1993).  Coping 
strategies can be divided into two broad categories: problem-focused coping and emotion-
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focused coping (Bombardier, D’Amico, & Jordan, 1990).  Problem-focused coping is aimed at 
managing the external or environmental aspects of a stressor.  In contrast, emotion-focused 
coping is aimed at regulating the affective consequences of a stressor.  Examples of problem-
focused coping in HIV include becoming active in one's medical regimen such as seeking out 
information about HIV, and making healthy lifestyle changes.  Examples of emotion-focused 
coping include avoidance and distraction including refusing to discuss HIV and attempting to 
forget about being HIV positive by not attending medical appointments (Kalichman, 1998).  
Reliance on emotion-focused coping strategies has generally been associated with poor 
adaptation to stressors (Moos & Schafer, 1993).   
Studies have shown that individuals with HIV who utilized problem-focused coping 
experience less psychological distress than those patients who utilized emotion-focused 
strategies such as avoidance (Namir, Wolcut, Fawzy, & Alumbaugh, 1987; Nicholson & Long, 
1990; Siegel, et al., 1997; Wolf, et al., 1991).  For example, Namir and her colleagues (1987) 
found that increased depression was associated with emotion focused coping in a group of men 
living with HIV/AIDS.  Emotion focused coping has not only been associated with depression, 
but also with increased disease progression. While, increased utilization of active coping 
strategies has been associated with reduced severity of HIV symptoms (Mulder, Antoni, 
Duivenvoorden, Kauffmann, & Goodkin, 1995; Solano, et al., 1993).  Problem-focused coping 
strategies have also been related to increased quality of life ratings and improved medical 
outcomes, including increased CD4 counts, for individuals with HIV (Friedland, Renwick, & 
McColl, 1996; Goodkin, et al., 1992).  
 Many studies have noted ethnic differences in coping and psychosocial adjustment.  In 
general, minorities tend to utilize emotion focused coping strategies rather than problem-focused 
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coping strategies (Plummer & Slane, 1996; Slavin, Rainer, McCreary & Gowda, 1991).  These 
results have also been confirmed in medical populations (Rodrigue, 1997).  However, there are 
mixed results concerning the role of ethnicity on coping strategies and subsequent adjustment to 
living with HIV (Heckman, et al., 1999; Lesserman, Perkins, and Evans, 1992; Singh et al., 
1999).   
 Lesserman and colleagues (1992) found that found that African American men with HIV 
expressed increased depressive symptoms and utilized more emotion focused coping strategies.  
These results were confirmed in a larger multi-site study (Singh, et al., 1999).  However, 
Heckman and colleagues (1999) came to the opposite conclusion, finding that a group of African 
American men demonstrated increased problem-focused coping and decreased depression.  The 
mixed results concerning coping style and subsequent psychological distress among ethnic 
minorities may have been caused by the use of restricted samples.  The above-mentioned 
research was conducted with homosexual male participants and may not be representative of 
other individuals with HIV.  Since rates of new HIV infections are rising fastest in the African-
American population and this population is confronted with many economic and cultural issues 
that complicate their adjustment to HIV, identification of potential variations in coping style is 
necessary.  Furthermore, the impact these coping strategies have on adherence may lead to the 
development of behavioral interventions (e.g., coping skills training) that would be helpful in 
improving overall quality of life for minority individuals (CDC, 1999). 
The Impact of Coping on Adherence 
 The strategies individuals use to adjust to the stressors associated with living with HIV 
disease may significantly impact whether these individuals fully participate in treatment.  
However, few studies have investigated the role of coping in adherence to HIV treatment.  Singh 
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and colleagues found that individuals, who reported increased utilization of problem-focused 
coping demonstrated increased adherence to HIV medications when compared to individuals 
who utilized emotion-focused coping (Singh et al., 1996; Singh, et al., 1999).   Other studies 
have also noted the importance of problem-focused coping (e.g. educating oneself about the 
disease and its treatment) in successful adherence to HIV medication regimens (Freeman, 
Rodriguez, & French, 1996; Kissinger, et al., 1995).  Although coping appears to impact 
medication adherence, there is little information available about the role of coping strategies in 
other behavioral aspects of adherence, such as appointment attendance.  
Limitations in the Current Adherence Literature 
 Most of the information we have concerning adherence to HIV treatment regimens is 
limited to medication intake, and may be neglecting many other important aspects of adherence. 
There are numerous behaviors associated with adherence including appointment attendance.  
Relatively few studies have examined these behavioral aspects of adherence to HIV treatment 
regimens.  This is unfortunate as these behaviors are necessary to ensure successful treatment.  In 
order to reduce drug resistance to the current medication regimens, the current HIV treatment 
guidelines dictate that patients not be placed on medication until they demonstrate significant 
progression of HIV related symptoms.  Thus, it is even more important that patients attend clinic 
visits for monitoring.  Patients must also attend medical appointments in order to receive any 
medical advice or prescriptions.  Once patients have started HIV medication regimens, frequent 
physician and nurse visits are required to ensure the medications are being taken as prescribed, 
gauge the success of the treatment regimen, and to prevent complications.  Consequently, non-
attendance to medical appointments can seriously interfere with treatment success.     
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 Recent evidence has demonstrated the importance of not limiting the scope of adherence 
to medication intake, thus neglecting other important aspects of adherence.  Lucas, Chaisson, & 
Moore (1999) identified missed appointments as the primary risk factor to HIV treatment failure 
at a large inner city HIV clinic.  Other studies have shown that variables that are not traditionally 
important in medication adherence may be important in appointment attendance.  For example, 
Kissinger (1995) found that patients who were most likely to miss appointments were African 
American, and had a history of IV drug use.  Other studies have found similar results with 
minority status and drug use history emerging as reliable predictors of appointment non-
attendance (Catz, et al., 1999; Israelaski, et. al., 2001; McClure, et al., 1999).  Israelaski (2001) 
and colleagues found that appointment non-attendance was highly associated with heterosexual 
African Americans.  This study included only demographic variables and accounted for 13% of 
the variance in appointment attendance.  This suggests that variables other than demographic 
characteristics may also be involved in missing clinic appointments (Catz et al., 1999; McClure 
et al., 1999).  The current study evaluated the impact of demographic variables, distress related 
factors, and coping style on appointment attendance.  
Summary 
 Advances in HIV treatment regimens have dramatically changed the long-term prognosis 
for people diagnosed with HIV.  When combination therapies were introduced, overall mortality 
and new AIDS cases declined for the first time since the beginning of the HIV/AIDS epidemic 
(CDC, 1999).  Thus with new treatments, HIV has become a treatable chronic illness that 
requires extensive clinical management (Kelly et al., 1998).  These medical regimens require 
significant time and effort from patients including frequent physician contact to monitor the 
course of the disease, determine appropriate treatments, and ensure the success of these 
 14 
treatments.  As with other chronic illnesses, many individuals have difficulty following medical 
recommendations and fail to attend medical appointments on a regular basis (Hecht, et al., 1998, 
Kissinger, 1995, Lucas et al., 1999).  Much of the current literature on HIV adherence involves 
medication adherence and may be missing an entire group of HIV patients who do not follow 
through with medical care long enough to receive medications or other available treatments and 
services.  Consequently, investigating factors that might be indicative of future likelihood of 
returning to treatment and can be easily obtained during initial contact with each patient is 
necessary. 
 Given the importance of attending medical appointments in successful clinical 
management of HIV, the present study attempted to identify important psychosocial and illness-
related variables that would reliably predict appointment attendance.  The primary purpose of the 
study was to determine if coping styles used by individuals with HIV would predict whether 
patients reliably attended scheduled medical appointments on a long-term basis.  Demographic 
factors (ethnicity, age, education, sexual orientation), illness severity (T-cell counts, symptom 
counts), and coping style (emotion-focused vs. problem-focused) were explored among a group 
of outpatients at an outpatient HIV medical clinic.  Specifically, the study addressed the 
following hypotheses:  
 Hypothesis 1) It was hypothesized that coping style (problem-focused vs. emotion-
focused) would predict appointment attendance above and beyond the variance predicted by 
demographic (ethnicity, age, gender, sexual orientation, education), illness related (symptom 
counts, T-cell counts), and distress related factors (depression, substance abuse).  Problem-
focused coping is characterized by actively managing aspects of a stressor, such as participating 
in ones treatment regimen; whereas, emotion-focused coping is characterized by emotional 
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responses including avoidance and re-appraisal of the stressor (Kalichman, 1998).  Problem-
focused coping has been consistently associated with improved adjustment to HIV related 
stressors, improved medical outcomes in HIV, and improved adherence to HIV medication 
regimens.  Consequently, problem-focused coping was expected to be predictive of reliable 
appointment attendance (Friedland et al., 1996, Goodkin et al., 1992; Siegel, et. al, 1997; Wolf 
et. al, 1991).  On the other hand, emotion-focused coping has been associated with increased 
psychological distress, complicated adjustment to HIV, and increased disease progression 
(Mulder et al., 1995, Soiano et al., 1993). Thus, emotion-focused coping was expected to be 
predictive of nonattendance to clinic appointments.  
 Hypothesis 2) It was hypothesized that demographic factors, particularly ethnicity, would 
impact coping style.  Specifically, minority individuals were expected to utilize more emotion-
focused coping strategies, while their Caucasian counterparts were expected to utilize more 
problem-focused coping strategies.  In general, the literature concerning ethnic differences in 
coping has shown that minority individuals demonstrate increased use of emotion-focused 
coping strategies (Plummer & Slane, 1996; Rodrigue, 1997; Slavin, Rainer, McCreary & Gowda, 
1991). However, this finding has not been consistent in adjustment to HIV related stressors 
(Heckman, et al.,1999; Lesserman, et. al, 1992; Singh et al., 1999).  The majority of this research 
has been conducted with restricted samples that consisted of male research participants.  The 
sample of participants in the current study was more balanced and provided a good opportunity 
to evaluate the effects of ethnicity on coping with HIV related stressors.  Since emotion-focused 
coping has been associated with increased distress (Namir et al., 1987; Nicholson & Long, 1990; 
Siegel et al, 1997, Wolf, et al., 1991) minority participants were also expected to report increased 
depressive symptoms.  
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 Hypothesis 3) It was hypothesized that participants with a history of substance abuse 
would utilize emotion-focused coping strategies more than problem focused coping strategies. 
Specifically, it was expected that participants with a history of substance abuse would utilize 
significantly more avoidant coping than participants who had no history of substance abuse.   In 
other populations, increased use of avoidant coping has been noted in individuals with a history 
of substance use (Avants, Warburton, & Margolin, 2000; Belding, Iguchi, & Lamb, Lakin, & 
Terry, 1996), but relatively little research exists about the relationship between coping strategy 
and history of substance use in individuals with HIV.   
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Methods 
Participants 
 Volunteers were recruited during their medical appointments at an ambulatory care HIV 
clinic (Early Intervention Clinic) located at Earl K. Long Medical Center (EKL).  This public 
teaching hospital in Baton Rouge, Louisiana is part of the Louisiana State University Medical 
School Campus and serves primarily low SES and uninsured individuals.  EKL Patients rarely 
utilize HIV services outside of this clinic.  Volunteers were eligible to participate in the study if 
they were able to read and were at least 18 years of age.  One hundred and sixty patients 
completed initial baseline evaluation.  Outpatient appointment attendance was obtained for a 
period of three years following completion of the baseline evaluation for each of these 
individuals.  The participants were predominately low income (mean yearly income= <$10,000 
per year) minority (African American= 65%), males (60.6%).  The mean age was 32 (SD= 7.9) 
years and mean education level was 12 years (SD=2.3).  Thirty five percent of the sample 
endorsed intravenous drug use.  Approximately 64% of the sample was heterosexual, while 36% 
were homosexual.  The homosexual participants were predominately male as only one female 
identified as homosexual.  Only 12.5 % of the minority participants identified as homosexual.  
Twenty-eight percent of participants were “asympotmatic” (T-cell count >500); 41% were 
“symptomatic” (T-cell count 200-500); and 24% were diagnosed with AIDS (T-cell count < 
200). 
Measures 
Demographics Questionnaire   
 A questionnaire concerning demographics and other information important to the population 
was administered (See Appendix A).  The form includes questions concerning age, gender, race, 
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education level, marital status, drug and alcohol use, and sexual preference.  This information 
was also obtained by a review of the patient’s medical record. 
Appointment Adherence 
 Appointment adherence data were obtained by conducting a retrospective chart review of 
each patient’s Early Intervention Clinic medical record(s).  Written records of each scheduled 
nurse or physician visit at were located and recorded.  Each scheduled clinic visit was 
documented as to whether the patient attended, canceled, or missed  (i.e., missing the 
appointment without canceling or rescheduling, “no shows”) the appointment.  This information 
was then used to calculate the total percentage of appointments attended during the three-year 
period.  The following formula was used: 
Appointments Attended 
Appointments Attended 
+ 
Appointments No-showed or Canceled 
 
Frequency of appointments scheduled may vary over time due to factors such as the patient’s 
health status, the patient relocating, or the physicians scheduling availability.  Consequently, the 
percentage of appointments attended was used rather than frequency of appointment attendance.  
When patients are in good health, appointments may only be scheduled every three to six 
months.  In order to allow the number of scheduled appointments to stabilize and to investigate 
the long-term impact of initial coping strategies, attendance data were collected for a total period 
of three years. 
Ways of Coping Questionnaire Adapted for HIV 
 The Ways of Coping Questionnaire (WCQ) is a 66-item scale designed to measure cognitive 
and behavioral coping strategies people use to manage their reactions to stressful events 
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(Folkman & Lazarus, 1988).  The WCQ questionnaire accounts for the dynamic nature of the 
coping process while also assessing tendencies toward problem-focused or emotion-focused 
coping.  
During administration of the WCQ participants were instructed to recall the most 
stressful situation related to being HIV positive they experienced in the past week. Next, they 
were asked to rate the extent to which they used certain coping strategies during this stressful 
encounter.  The response format is a four-point Likert scale that ranges from 0 (not used) to 4 
(used a great deal).  Factor analysis of the WCQ revealed eight coping scales including 1) 
confrontive coping, 2) distancing, 3) self-controlling, 4) seeking social support , 5) accepting 
responsibility, 6) escape-avoidance, 7) planful problem solving, and 8) positive reappraisal 
(Folkman & Lazarus, 1988). The planful problem solving scale is representative of problem-
focused coping; whereas, six of the other scales are representative of emotion-focused coping 
(distancing, self controlling, accepting responsibility, escape-avoidance, confrontive coping, and 
positive reappraisal).  The seeking social support scale contains both problem-focused and 
emotion-focused coping items and cannot be considered to be indicative of a single form of 
coping.   See Appendix B for a description of these coping scales.  These scales can be 
considered separately or combined to obtain a total coping score (Folkman & Lazarus, 1988).   
 The WCQ has demonstrated good reliability and validity.  The items were originally 
obtained by having individuals list the coping strategies they use in stressful situations. The 
authors consider this to be evidence of face validity.  Construct validity was established by 
demonstrating congruence between theoretical predictions and research supporting coping as a 
process that consists of both problem-focused and emotion-focused strategies (Folkman & 
Lazarus, 1980; Folkman, Lazarus, Dunkel-Schetter, DeLongis, & Gruen, 1986; Folkman & 
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Lazarus, 1988).  Due to the dynamic nature of the coping process, traditional test-retest 
reliability statistics are not provided.  However, the authors reported measures of internal 
consistency with alpha coefficients ranging from .79 (Positive Reappraisal) to .61 (Distancing).  
The WOC questionnaire has been used successfully in research regarding coping with a variety 
of chronic illnesses including HIV (Namir, et al., 1987; Singh, et al., 1996). 
Center for Epidemiological Studies Depression Scale (CES-D) 
 The CES-D is a 20-item self-report depression inventory that emphasizes the cognitive 
aspects of depression rather than somatic complaints(Radloff, 1977).  Consequently, the CES-D 
is ideal for use with medical populations.  Individuals rate the frequency of depressive 
symptomology over the past week.  The response format is a four point Likert scale that ranges 
from 0 (none of the time) to 3 (most or all of the time).  Total scores range from 0 to 60 with 
scores above 16 indicating the presence of depression.  Higher scores are indicative of increased 
depressive symptoms.   
Substance Abuse 
 Substance abuse was measured in the following manner.  First, substance abuse history 
was established via interviews with the patients during their initial appointments with at the HIV 
clinic.  The presence of substance abuse was documented from progress notes made during each 
clinic visit.  This information was used to obtain a measure of current substance abuse.  Current 
substance abuse was defined as the presence (as indicated by medical record) of substance abuse 
during the three year time period.  
Illness Severity  
 As discussed above, the principle target cell of HIV includes T-cells. Thus, a good and 
reliable measure of illness severity can be obtained by collecting absolute T-cell counts from 
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blood draws.  Baseline T-cell counts were obtained through a chart review of routine laboratory 
reports.  These T-cell counts were used as an index of illness severity.  Additional information 
concerning illness severity was obtained by collecting baseline symptom counts.  Baseline 
symptom counts are routinely collected during medical intake as a measure of illness severity. 
Increased symptoms occur with more progressed HIV infection and indicate greater illness (Fan 
et al., 2000).  Symptom counts can range from 0 to 20.  See Appendix C for a list of pertinent 
symptoms included in this count.    
Procedure 
Attendance information the current study was obtained through a retrospective review of 
the participants’ medical records. Baseline data collection occurred between 1992 and 1995.  
Volunteers were consecutively recruited during their initial appointments with the HIV 
outpatient clinic.  Participants included individuals who had been diagnosed with HIV and were 
receiving outpatient medical treatment at the above-mentioned clinic (EKL).  Informed consent 
was obtained prior to participation in the study (see Appendix D).  Demographic information 
was obtained from patient interviews conducted during the initial clinic appointment and from 
the baseline demographics questionnaire completed by patients.  Information concerning disease 
status and other medical information was obtained through a review of the patients’ medical 
records at baseline.  Participants were paid five dollars for completion of the baseline 
questionnaires. 
Following baseline data collection all scheduled clinic appointments, including physician 
and nurse visits, were monitored via chart reviews for a period of three years from the patient’s 
entry into the study.  Appointment attendance information (frequency of scheduled, canceled, 
and “no show” appointments) was obtained from a retrospective review of the patients’ medical 
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records.  When available, other important information such as changes in attending physician 
and reason for discharge from the clinic (e.g. deceased, relocating) was also recorded during 
examination of the patients’ medical records.  
Research Design 
 A retrospective review of the medical records was conducted  in order to determinethe 
frequency of   participants’ appointment adherence on a long-term basis.  The primary focus of 
the study was to determine the predictive value of coping strategies on appointment attendance 
above and beyond demographic factors, illness severity, and distress variables (substance abuse, 
depression). Participants completed baseline data and their medical attendance was tracked for a 
period of three years.  As to maximize predictive validity over time, only individuals who 
completed the three years of treatment and did not drop out for any reason (e.g., death relocation, 
lost to follow-up) were included in the multiple regression analysis. Analysis of individuals who 
were classified as “attenders” and “nonattenders” was conducted on an annual basis.   
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Results 
Analysis of Demographic Data 
 A total of 160 participants completed baseline evaluation measures.  Appointment 
attendance was retrospectively tracked over a three-year period.  Three years following intake, 
83 individuals remained in treatment at the clinic.  Clinic appointments are often scheduled on an 
irregular basis and appointments may be scheduled as few as three to four times yearly.  
Consequently, attempts were made to maximize predictive validity in the current study and only 
individuals who completed the three years of treatment and did not drop out for any reason (e.g., 
death relocation, lost to follow-up) were included in the multiple regression analysis.  Although 
this procedure introduces a selection threat to validity, the data set remained strong and did not 
suffer greatly due to this selection bias.  Demographic characteristics of the two samples were 
very similar and no significant differences occurred between the two samples.  A comparison of 
the total sample (N=160) and the sample included in the regression analysis (N=83) is presented 
in Table 1.  Analysis of the regression residuals also reveals an approximate normal distribution.  
These results can be found in Figure 1.  
     The regression sample consisted primarily of African American males with an average of 12 
(SD=2.36) years of education. The average age of the participants was approximately 33 
(SD=7.83) years old.   
Means and standard deviations were computed for the independent variables of interest 
including T-cell counts, symptom counts, CES-D scores, and for each of the WCQ scales.  These 
results can be found in Table 2.  On average participants reported relatively few HIV symptoms 
and T-Cell counts above the level required for an AIDS diagnosis.  Thus, most of the sample did 
not exhibit symptoms associated with severe illness.  The sample reported increased depressive 
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symptoms, as the mean score on the CES-D (M=21.89) was above the score, which is indicative 
of elevated depressive symptoms (16). 
     Table 1. Sample Comparison: Demographic Characteristics  
                                             Total Sample 
                                             (N=160) 
Regression Sample 
(N=83) 
 
Variable N % N % 
Gender 
    Male 
    Female 
 
97 
63 
 
60.6 
39.4 
 
48 
35 
 
57.8 
42.2 
 
Ethnicity 
     Caucasian 
     Minority   
  
 
 
104 
53 
3 
 
 
65.0 
33.1 
1.9 
 
 
32 
51 
 
 
 
38.6 
61.4 
 
Orientation 
     Heterosexual 
          Caucasian 
          Minority  
          Male 
          Female 
     Homosexual/Bisexual 
          Caucasian 
          Minority  
          Male 
          Female 
 
 
102 
17 
83 
41 
61 
57 
36 
20 
56 
1 
 
 
63.8 
10.6 
51.9 
25.6 
38.1 
35.6 
22.5 
12.5 
35 
.63 
 
 
50 
9 
41 
16 
34 
33 
23 
9 
32 
1 
 
 
60.2 
10.8 
49.4 
19.3 
41.0 
39.8 
27.7 
10.8 
38.6 
1.2 
 
IV Drug Use History 
     Caucasian 
     Minority  
     Male 
     Female 
 
56 
14 
41 
39 
1 
 
35.0 
8.8 
25.6 
24.4 
.6 
 
24 
7 
17 
18 
6 
 
28.9 
7.4 
20.5 
21.7 
7.2 
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               Table 2. Descriptive Statistics of Study Completers  
Variable M (SD) Range 
Symptoms 2.30 (2.37) 0-13 
T-Cell Count 422.02 (296.35) 30-1554 
CES-D 
 
21.89 (13.04) 0 – 55 
WCQ 
   Confrontive 
   Distancing 
   Controlling 
   Seeking Social Support 
   Accepting Responsibility 
   Escape-Avoidance 
   Planful Problem Solving 
   Positive Reappraisal 
 
 
7.24 
9.63 
12.02 
9.90 
6.07 
11.78 
9.80 
13.30 
 
 
3.95 
3.95 
3.87 
4.21 
2.95 
4.99 
4.20 
4.87 
 
0-16 
1-17 
2-20 
0-18 
0-12 
0-23 
2-21 
2-21 
 
Pearson correlations were computed to examine possible significant relationships 
between demographic factors, illness severity factors, depression, and total percentage of 
appointments attended.  Increased education was significantly correlated with fewer depressive 
symptoms on the CES-D.  Total attendance was negatively correlated with T-cell counts and 
depressive symptoms.  The correlation matrix of demographic and medical variables is located in 
Table 3.  As expected each of the WCQ scales were significantly intercorrelated, indicating that 
the current participants interpreted the WCQ in a similar fashion to the validation sample. These 
results can be found in Table 4. 
Significant correlations were also noted between the CES-D and several emotion-focused coping 
scales of the WCQ including confrontive (r (80) = .43, p< .01), distancing (r (80) = .26, p< .05), 
self-controlling (r (80) = .30, p< .01), accepting responsibility (r (80) = .48, p< .01), and escape-
avoidance (r (80) = .47, p< .01).  Education was negatively correlated with the confrontive (r 
(83) = -.31, p< .01), seeking social support (r (83) = -.24, p< .05), and escape avoidance (r (83) = 
-.26, p< .05) subscales of the WCQ.  Total percent attendance was negatively correlated with 
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emotion-focused scales of the WCQ including confrontive (r (83) = -.42, p< .01), self-controlling 
(r (83) = -.26, p< .05), accepting responsibility(r (80) = -.33, p< .01), and escape-avoidance (r 
(83) = -.23, p< .05). 
          Table 3. Correlation Matrix:  Demographic and Medical Variables  
 1 2 3 4 5 6 
1. Age - .42 -.07  -.10 -.03 .18 
2. Education  - -.14 -.12 -.24* .17 
3. Symptoms   - -.05 .10 -.04 
4. T-Cell Count    - -.04 -.23* 
5. CES-D 
 
    - -.30** 
6. Total % Attendance 
 
     - 
      *p<.05 
     **p<.01 
 
 
Table 4. Correlation Matrix:  Intercorrelations among WCQ Scales  
 1 2 3 4 5 6 7 8 
1. Confrontive - .47** .50**  .48** .61** .62** .42** .29** 
2. Distancing  - .51** .24* .52** .61** .45** .37** 
3. Self-Controlling   - .33** .56** .56** .53** .52** 
4. Seeking Social Support    - .35** .29** .44** .52* 
5. Accepting       
Responsibility 
 
    - .59** .52* .34** 
6. Escape-Avoidance 
 
     - .37** .26* 
7. Planful Problem Solving 
 
      - .58** 
8. Positive Reappraisal 
 
       - 
*p<.05 
**p<.01 
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T-tests were computed to determine the presence of any significant group differences 
between gender, ethnicity, and participants with a history of intravenous drug use on illness 
related factors, coping strategies, or total percentage of appointments attended.  A Bonferroni 
correction was used to control for the overall error rate associated with performing multiple t-
tests. An adjusted significance level of .004 was used for the following analyses. Results 
indicated that females (M=545) demonstrated significantly higher T-cell counts (t (47)  = 2.98, p 
= .004) than males (M=338). Females (1.43) also demonstrated fewer HIV related symptoms (t 
(78)  = -3.05, p = .003) than males (M=2.98).  When compared to Caucasians (M=309), 
minorities (M=495) demonstrated higher T-cell counts (t (74) = -3.22, p = .002).  Minority 
individuals (M=66.8%) also demonstrated significantly decreased percentage appointment 
attendance (t (79) = 4.39, p < .001) when compared to Caucasians (M=82%).  Minoritiy 
participants (M=14.47) utilized more of the emotion focused coping technique, positive 
reappraisal (t (80)  = -2.88, p = .004) than Caucasian participants (M=11.41).  Participants who 
reported a history of intravenous drug use (M=9.79) were more likely to use confrontive ways of 
coping (t (80) = -4.16, p < .001) than participants with no prior drug use history (M=6.14).  
Analysis of Total Attendance 
    A wide range of variability was noted in the attendance data, indicating that range 
restriction did not limit the validity of the current data set. The average attendance (N=107) for 
the total three-year period was 70% with scores ranging from 0% to 100%. Average attendance 
for year one (N=160) was 71 % (range= 0-100), year two (N=104) was 66% (range= 0-100), and 
year three was 65% (range = 0-100). As mentioned above, total percentage attendance was 
significantly and negatively correlated with T-cell counts and depression.  
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Analysis of Coping and Attendance 
 Correlational analysis was conducted to determine the strength of association between 
coping strategies and total attendance.  Total percentage attendance was significantly and 
negatively associated with emotion focused coping strategies including confrontive (r (96) =  -
.31, p = .001), self-controlling (r (97) = -.23, p = .02), accepting responsibility (r (97) = -.27, p = 
.005), and positive re-appraisal (r (97) = -.23, p = .02).  The relationship between coping and 
appointment attendance was also evaluated on an annual basis.  Only one emotion-focused 
coping strategy remained significantly correlated with appointment attendance for each of the 
three years and total percentage attendance.  Confrontive coping was significantly associated 
with appointment attendance in year one (r (155) = -.20, p = .02), year two (r (104) = -.23, p = 
.02), and year three (r (96) = -.24, p = .02).  Distancing (r (156) = -.25, p = .002), self-controlling 
(r (156) = -.22, p = .005), and escape-avoidance, (r (156) = -.16, p = .05) was significantly 
associated with attendance in year one.  Accepting responsibility was significantly correlated 
with attendance in year one (r (156) = -.17, p = .04) and year two (r (104) = -.26, p = .009).  
Proportional data are particularly susceptible to skewness and may not be normally 
distributed (Cohen & Cohen, 1983).  The procedure for determining if a score transformation is 
appropriate for a data set that was suggested by Cohen & Cohen (1983) was conducted with the 
current data set.  Residual scatterplots were examined for linear irregularities.  The data for total 
percent attendance did not require score transformations, as the data approached a normal 
distribution that was significantly disrupted by a score transformation.  See Figure 1 for the 
histogram of regression residuals.  
Regression analysis was conducted to explore the effects of coping on appointment 
attendance using a hierarchical regression procedure.  In order to control for variables that may 
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significantly impact attendance, these variables (i.e., age, sex, race, education, sexual orientation, 
HIV related symptoms, T-cell counts, intravenous drug use, and CES-D scores) were entered in 
the first block of the regression model as a set.  For the second block, emotion focused coping 
scales (confrontive, distancing, self-controlling, accepting responsibility, escape-avoidance, 
positive reappraisal, seeking social support) were entered in a stepwise fashion.  Finally, 
problem-focused coping (planful problem solving) was entered in the third block in a stepwise 
fashion.   
Standardized Regression Residual
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Figure 1. Histogram of Regression Residuals 
The overall regression model did not support the hypothesis that coping skills would 
predict variance in long-term appointment attendance beyond the level of prediction offered by 
demographic and distress related (CES-D, intravenous drug use) variables.  The regression 
model revealed that minority status (Beta = -.25), intravenous drug use (Beta = -.36), and 
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depression (Beta = -.23) were highly associated with appointment attendance (R2 (9, 64) = .30, p 
< .001).  Analysis of squared semipartial correlation coefficients indicate that intravenous drug 
use accounted for the most variance (8%) with ethnicity and depressive symptoms accounting for 
4% of the variance in appointment attendance. See Table 5 for a summary of the hierarchical 
regression analysis.   Post-hoc power analysis was conducted following the procedure suggested 
by Cohen (1992) and a moderate degree of power (.72) was estimated. 
Table 5. Multiple Regression Analysis: Coping and Appointment Adherence  
 
Variable 
 
∃ 
 
t 
Squared  
Semipartial 
Correlation 
Age .19 1.79 .03 
Gender .23 1.45 .02 
Ethnicity 
Education 
-.25 
-.08 
-2.04* 
-.71 
.04 
.005 
Sexual Orientation 
Intravenous Drug Use 
T-Cells 
HIV Symptom Count 
Depressive Symptoms 
 
-.07 
-.36 
-.19 
-.08 
-.23 
 
-.50 
-2.95** 
-1.73 
-.75 
-2.12* 
.002 
.08 
.03 
.005 
.04 
                  *p<.05 
               **p<.01 
Analysis of Attenders vs. Nonattenders on an Annual Basis 
 Since the multiple regression analyses was conducted on a subset of the total sample, 
further analysis evaluating factors relating to appointment attendance on an annual basis was 
necessary. This will allow for determination regarding the relative contribution (if any) of  
significant results found in the multiple regression analysis. To further examine group 
differences in attendance by year, chi square analysis was conducted.  For the following 
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analyses, “attenders” were defined as attending at least 80% of scheduled appointments within 
the year.  The total sample (N=160) was used to conduct the following analyses.  This allows for 
an evaluation of factors related to attendanceon an annual basis.  Individuals with less than 80% 
total attendance were classified as “nonattenders”.  Eighty percent adherence has typically been 
used as a gold standard to measure “successful adherence” in medication adherence.  Because 
relatively few studies regarding HIV appointment attendance exist, no prior studies have 
classified individuals as “attenders” vs. “nonattenders” using a percentage of total appointments.  
Consequently, the known gold standard was utilized for this study.  A stricter definition of 
adherence would have also significantly reduced sample size and not have allowed for 
comparisons between these two groups.  Since only three participants were Hispanic and the rest 
of the minority sample was African American, ethnicity was grouped as Caucasian and Minority.  
Bonferroni corrections were used in interpreting the significance of each chi square test.  The 
following analyses were interpreted based on an alpha level of .004. 
Analysis of Attenders vs. Nonattenders by Ethnicity 
 The chi-square test of independence was used to determine if attendance to medical 
appointments was dependent on demographic group membership for each year of the study.  
When expected attendance was compared among Caucasian and Minority participants, chi 
square tests were significant for year one, χ2 (df = 1, N = 160) = 10.84, p = .001, and year two, 
χ2(df = 1, N = 104) = 15.41, p < .001, but not year three.  Thus, Minority participants 
demonstrated higher levels of appointment nonattendance than their Caucasian counterparts 
during year one and year two.  These chi square results can be found in Table 6 – Table 8. 
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 Table 6. Year One: Chi-square Test of Independence for Attendance: Ethnicity  
Variable Caucasian Minority χ2 df Significance 
Attendance      
     Yes 28 31 10.84 1 p = .001 
     No 
 
25 76    
 
  Table 7. Year Two: Chi-square Test of Independence for Attendance: Ethnicity  
Variable Caucasian Minority χ2 df Significance 
Attendance      
     Yes 27 22 15.41 1 p < .001 
     No 
 
10 45    
   
Table 8. Year Three: Chi-square Test of Independence for Attendance: Ethnicity  
Variable Caucasian Minority χ2 df Significance 
Attendance      
     Yes 17 22 1.71 1 p = .28 
     No 
 
9 39    
 
Analysis of Attenders vs. Nonattenders by Gender 
 The chi-square test of independence was used to determine if attendance to medical 
appointments was dependent on gender during each year of the study.  When expected 
attendance was compared among male and female participants, significant differences were only 
noted in year two χ2 (df = 1, N = 104) = 16.36, p < .001, with males being more likely to attend 
appointments than males.  These Chi square results can be found in Table 9 – Table 11. 
Table 9. Year One: Chi-square Test of Independence for Attendance: Gender  
Variable Male Female χ2 df Significance 
Attendance      
     Yes 38 21 .56 1 p = .45 
     No 
 
21 42    
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Table 10. Year Two: Chi-square Test of Independence for Attendance: Gender  
Variable Male Female χ2 df Significance 
Attendance      
     Yes 38 11 16.36 1 p < .001 
     No 
 
59 34    
 
Table 11. Year Three: Chi-square Test of Independence for Attendance: Gender  
Variable Male Female χ2 df Significance 
Attendance      
     Yes 24 18 .10 1 p = .75 
     No 
 
28 24    
 
Analysis of Attenders vs. Nonattenders by Sexual Orientation  
 The chi-square test of independence was used to determine if attendance to medical 
appointments was dependent on sexual orientation.  When expected attendance was compared 
among participants who identified as heterosexual and homosexual, significant differences were 
noted in year two only χ2(df = 1, N =104) = 9.54, p = .002, with participants who were 
heterosexual participants being less likely to attend appointments than participants who were 
homosexual.  These chi square results can be found in Table 12 – Table 14. 
Table 12. Year One: Chi-square Test of Independence for Attendance: Orientation  
Variable Heterosexual Homosexual χ2 df Significance 
Attendance      
     Yes 34 25 1.74 1 p = .19 
     No 
 
68 32    
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Table 13. Year Two: Chi-square Test of Independence for Attendance: Orientation  
Variable Heterosexual Homosexual χ2 df Significance 
Attendance      
     Yes 22 27 9.54 1 p = .002 
     No 
 
41 14    
 
Table 14. Year Three: Chi-square Test of Independence for Attendance: Orientation  
Variable Heterosexual Homosexual χ2 df Significance 
Attendance      
     Yes 24 18 1.03 1 p = .311 
     No 
 
35 17    
 
Analysis of Attenders vs. Nonattenders by Intravenous Drug Use History  
 The chi-square test of independence was used to determine if attendance to medical 
appointments was dependent on history of intravenous drug use (IV Drug Use).  When expected 
attendance was compared among participants with and without a history of intravenous drug use, 
no significant differences were noted.  These chi square results can be found in Table 15 – Table 
17. 
Table 15. Year One: Chi-square Test of Independence for Attendance: IV Drug Use 
Variable IVDU No IVDU χ2 Df Significance 
Attendance      
     Yes 18 40 .778 1 p = .378 
     No 
 
38 62    
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Table 16. Year Two: Chi-square Test of Independence for Attendance: IV Drug Use 
Variable IVDU No IVDU χ2 Df Significance 
Attendance      
     Yes 13 36 1.77 1 p = .183 
     No 
 
21 33    
 
Table 17. Year Three: Chi-square Test of Independence for Attendance: IV Drug Use 
Variable IVDU No IVDU χ2 df Significance 
Attendance      
     Yes 8 34 4.96 1 p = .026 
     No 
 
21 31    
 
Analysis of Attenders vs. Nonattenders by Current Substance Abuse 
 The chi-square test of independence was used to determine if attendance to medical 
appointments was dependent on current substance abuse as noted by physicians and nurses 
during clinic visits.  When expected attendance was compared among participants with and 
without current substance abuse, no significant differences were noted in year one or year two. 
Because only two participants were noted to have difficulty with substance abuse, analysis of 
year three data could not be conducted. These chi square results can be found in Table 18 – 
Table 19. 
     
          Table 18. Year One: Chi-square Test of Independence for Attendance: Substance Abuse 
Variable Substance 
Abuse 
No Substance  
Abuse 
χ2 Df Significance 
Attendance      
     Yes 4 18 3.83 1 p = .04 
     No 
 
55 83    
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          Table 19. Year Two: Chi-square Test of Independence for Attendance: Substance Abuse 
Variable Substance 
Abuse 
No Substance  
Abuse 
χ2 Df Significance 
Attendance      
     Yes 5 44 .28 1 p = .43 
     No 
 
4 51    
 
Analyses of Attrition-Related Variables 
  The data were examined to determine the frequency of attrition over the three-year study 
period and to investigate potential demographic group-related variables. During the first year of 
the study 6 participants died (3.8%), 15 participants were lost to follow-up (9.6%), and 7 
participants appropriately transferred their care to another medical clinic (4.5%).  During the 
second year of the study, 9 participants died (7.5%), 21 participants were lost to follow-up 
(17.5%), and 3 participants appropriately transferred their care to another medical clinic (2.5%). 
During the third year of the study, 1 participant died (.9%), 17 participants were lost to follow-up 
(15.9%), and 5 participants appropriately transferred their care to another medical clinic (3.2%). 
The presence of current substance abuse steadily declined as the study progressed beginning with 
21 participants (13.5%) in year one, and declining to 9 participants (7.5%) in year two and 2 
participants (1.9%) in year three.  See Table 20 for these results. 
     Table 20. Percentage of Sample Attrition by Study Year  
 Death Lost to Follow-Up Appropriate Transfer  
Year One 3.8% (N=6) 9.6% (N=15) 4.5% (N=7) 
 
Year Two 7.5% (N=9) 17.5% (N=21) 2.5% (N=3) 
 
Year Three .09% (N=1) 15.9% (N=17) 3.2% (N=5) 
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  In order to determine if significant group differences occurred in attrition, chi square tests 
of independence were conducted.  Men were more likely to be lost to follow-up than females in 
year one, χ2(df = 1, N = 156) = 5.04, p = .025.  Minorities were more likely to be lost-to follow-
up in year two,  χ2(df = 1, N = 129) = 6.745 p = .009.  Also, having a history of intravenous drug 
use in year one made substance abuse in year one of the study more likely χ2(df = 1, N = 154) = 
8.14, p = .004.  No other significant differences were found between groups (ethnicity, gender, 
orientation, intravenous drug use) on attrition related variables. 
  The largest reason for attrition in the current study was loss to follow up.  This indicates 
that many participants failed to return to the clinic with no warning and effectively dropped out 
of treatment.  If these individuals did not seek treatment at other facilities, they may have posed 
an increased risk of further transmitting HIV to others.  To further examine factors associated 
with participants who were lost to follow up in the current study, a multiple regression analysis 
was conducted.  Demographic factors (gender, ethnicity, age, education, and sexual orientation), 
illness related factors (T-cell count, symptoms count), and distress related variables (intravenous 
drug use history, current substance abuse, and depressive symptoms) were entered into a 
regression equation to determine if these variables significantly predicted individuals who 
dropped out of treatment.  Separate analyses were conducted for each study year. Significant 
results were only noted in year one.  The regression revealed that in year one of the study 
participants who were of younger age (Beta= -.194), male (Beta=. 362), and demonstrated 
increased depressive symptoms (Beta=. 228) were more likely to be lost to follow up (R2 (10, 
118) = .17, p = .01). See Table 22 for a summary of these results. 
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         Table 22. Multiple Regression Analysis: Lost to Follow Up  
 
Variable 
 
∃ 
 
t 
Squared  
Semipartial 
Correlation 
Age -.19 -2.05* .03 
Gender .36 2.98** .06 
Ethnicity 
Education 
-.21 
.05 
1.96 
.53 
.03 
.04 
Sexual Orientation 
Intravenous Drug 
Use 
T-Cells 
HIV Symptom 
Count 
Depressive 
Symptoms 
 
-.06 
-.01 
.06 
-.16 
-.23 
 
-.46 
-.05 
.60 
-1.6 
2.58* 
.001 
.00006 
.003 
.02 
.05 
                          *p<.05 
                          **p<.01 
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Discussion 
 The results of the current study did not support the primary hypothesis that coping 
strategies would significantly predict appointment attendance above and beyond other 
demographic and distress related variables on a long-term basis.  Multiple regression analysis 
revealed the coping style that participants used to adjust to HIV-related stressors did not impact 
their appointment attendance over a three-year follow-up period.  Although the study failed to 
support the primary hypothesis, important findings were noted.  Demographic factors including 
ethnicity, history of intravenous drug use, and depressive symptoms predicted future adherence 
with medical appointments on a long-term basis.  Specifically, minority status, increased 
endorsement of depressive symptoms, and a positive history of intravenous drug use was 
associated with higher levels of appointment non-attendance.  These results must be interpreted 
with caution as they were only noted during a regression analysis of a highly selective sample of 
individuals who remained in treatment for a three-year time period.  Analysis of the entire 
sample on an annual basis only showed that ethnicity was an important factor related to 
nonattendance in year one and two of the study.  Consequently, generalizability of the current 
results is limited. 
Appointment Attendance 
Ethnicity and Appointment Attendance   
 Ethnicity was predictive of failure to attend HIV clinic appointments for a period of three 
years after initial contact with the clinic.  Although other studies have noted decreased 
appointment attendance among minority individuals (Catz, et al., Israelaski, et. al., 2001; 
McClure, et al., 1999), this is the first known study to evaluate the impact of psychosocial factors 
in appointment adherence on a long-term basis.  The current results add to a growing body of 
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literature finding that minority individuals demonstrated reduced attendance to scheduled HIV 
clinic appointments.  However, none of these studies have investigated the specific variables 
associated with minority individuals that lead to decreased appointment adherence.  Given that 
minority status continues to impact appointment attendance on a long-term basis, research 
regarding these issues is necessary.  Factors related to socioeconomic status (SES) such as 
inadequate financial means, poor access to medical care, limited education, and poor community 
support have been found to be important in adherence in other chronic illnesses and may also be 
important in individuals with HIV (Rimer, et al., 1996).  Since these factors were not part of the 
primary hypotheses being evaluated, the current study was unable to adequately examine these 
variables.  For example, the present sample was comprised of indigent individuals with 
approximately 87% of the sample reporting annual incomes at or below $10,000 and did not 
allow for analysis of income-related variables.  The only other variable related to SES in the 
current study included education.  Education level was not significantly related to attendance 
variables, but was related to increased depressive symptoms. 
Depressive Symptoms and Appointment Attendance 
 Depressive symptoms have been found to negatively impact adherence with HIV 
treatment regimens (Bogart, et al., 2000, Catz, et al., 2000; Kalichman et al., 2000; Rabkin & 
Chesney, 1999).   The current study showed that increased depression at clinic intake was 
associated with higher levels of appointment non-attendance over a three year time period.  Thus, 
increased presence of depressive symptoms may be a risk factor not only for medication 
adherence, but also for failing to meet other HIV treatment requirements like appointment 
attendance.   
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 Failure to attend appointments can have serious consequences on overall health and well 
being for individuals with HIV (Lucas et al., 1999).  Since depression appears to be a major risk 
factor for adherence difficulties, HIV clinics should address this issue with all patients.  The 
results of this study suggest that including a psychometrically sound screening instrument during 
initial contact with patients may help identify individuals who are risk for failing to attend 
regularly scheduled appointments on a long term basis.  This information can be used to develop 
targeted interventions aimed at preventing appointment nonadherence.  Many clinics already 
obtain information concerning depressive symptoms, but may not administer a standardized 
scale, which would ensure adequate assessment of depressive symptoms.  Screening for 
depressive symptoms is straightforward, can be easily included in the intake process, and has the 
potential to greatly benefit patients.   
 Increased depressive symptoms were noted in the current sample.  The mean CES-D 
score (M=21.89) was above the cutoff score (16) indicating the presence of significantly elevated 
depressive symptoms.  Although not found in all samples, the current increased level of reported 
depressive symptoms in individuals with HIV is consistent with prior literature (Heckman, et al., 
1999; Griffin & Rabkin, 1997).  Griffin and Rabkin (1997) noted that increased depressive 
symptoms frequently occur in research studies conducted in clinic settings, particularly when the 
assessments were obtained at clinic intake.  A large amount of variability also existed in this data 
(SD=13.04).  Thus, the majority of depressive symptoms may have been experienced by certain 
segments of the sample.  Increased depressive symptoms were associated with individuals who 
had decreased levels of education.  Consequently, the current results regarding depression and 
long-term appointment attendance should be interpreted with caution and future studies 
replicating these effects would be useful. 
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Intravenous Drug Use History and Appointment Attendance   
A history or intravenous drug abuse emerged as an important predictor of appointment 
attendance on a long-term basis.  This is consistent with previous literature concerning history of 
illicit drug use and appointment attendance (Kissinger, et al., 1995; McClure, et al., 1999).  The 
current results showed that a history of intravenous drug use remains an important risk factor for 
failure to attend appointments even three years after intake into the clinic.  This highlights the 
importance of obtaining detailed information concerning drug use history, as past substance 
abuse is highly associated with continued use during treatment. The longer individuals were in 
treatment, the less likely they were to demonstrate current substance abuse.  Outside of coping 
style, the current study was not specifically designed to evaluate factors related to substance use 
that negatively impact appointment attendance.  However, the current results suggest that 
understanding the relationship between substance abuse and treatment adherence behaviors is 
needed.  The current results coupled with evidence that substance abuse interferes with 
medication adherence suggest that a primary method to increase HIV treatment adherence in 
individuals with substance abuse may be to help them reduce or eliminate their substance use 
(Eldred et al., 1998). 
Coping 
Coping and Appointment Attendance 
 Appointment attendance over a three-year period was negatively associated with 
emotion-focused coping including confrontive, self-controlling, accepting responsibility, and 
positive reappraisal coping strategies.  Of these strategies, a confrontive coping strategy 
remained negatively associated with appointment attendance during each year of the study.  This 
suggests that individuals who handle problems or stressors through destructive or risky means 
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are more likely to demonstrated reduced appointment attendance.  Other emotion focused coping 
appeared to have more of a negative impact on coping during the first year of treatment.  These 
results were noted during correlational analysis and did not maintain their significance when 
demographic, illness-related, and distress-related factors were entered into a multiple regression 
analysis. 
 The current study showed that coping style (emotion-focused vs. problem-focused) did 
not significantly impact appointment adherence.  However, other studies have found that coping 
is an important variable in improving HIV treatment adherence (Singh, 1996, Singh, 1999).  
Explanations for the discrepancy of these results must be explored.  Prior studies that have noted 
the importance of coping in HIV treatment have been conducted with combination medication 
regimens.  It may be the case that coping strategy is important to medication adherence and not 
to appointment attendance.  Medication adherence requires continuous effort on a daily basis 
from patients; whereas, appointment attendance occurs on an irregular basis and tend to be 
scheduled at varying time intervals.   
 The coping literature suffers from a lack of cohesiveness, with researchers using different 
definitions of coping and different measures to assess coping skills.  It may be the case that these 
variations in methodology also produce variations in research results.  The current study 
evaluated coping during initial contact with the patient and did not analyze coping on a 
longitudinal basis.  Although we attempted to stabilize the coping measure by concentrating on 
HIV-related stressors, this procedure may not have fully accounted for the dynamic nature of the 
coping process.  Initial coping strategies may not influence long-term adherence behaviors due to 
changes in coping over time.  The current study also utilized a situation (i.e., being diagnosed 
with HIV and attending treatment) that is perceived as uncontrollable rather than measuring an 
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individual’s perception of controllability of HIV-related stressors.  Although this is a common 
methodological shortcoming in studies of coping, it still does not give us a true indication of the 
effects of coping on behavioral aspects of adherence.  Ideally, coping should be evaluated 
repeatedly over time and include perceptions of the participants perceived controllability over the 
stressors (Park, Folkman, & Bostrom, 2001).   
Coping and Ethnicity 
 It was hypothesized that minority individuals would utilize significantly more emotion-
focused coping strategies and report increased levels of depression when compared to their 
Caucasian counterparts.  The current results revealed that minorities utilized emotion-focused 
coping strategies more than problem-focused coping strategies.  Specifically, minority 
participants in this study were more likely to utilize positive reappraisal as a specific coping 
strategy.  These results are consistent with a growing body of evidence highlighting ethnic 
differences in coping with HIV-related stressors (Heckman, et al., 1999; Lesserman, et al., 1992; 
Singh et al., 1999).   
 However, minority individuals (primarily African Americans) did not endorse 
significantly increased depressive symptoms when compared to Caucasian participants.  
Although, these results differ from some published studies (Leserman et al., 1992; Singh et al., 
1999), they are consistent with at least one other research study that included primarily low-
income African American participants (Heckman et al., 1999).  These results suggest that 
emotion-focused coping is not inevitably a negative influence on the adjustment process. There 
was no evidence in the current study to suggest that problem-focused coping is associated with 
decreased endorsement of depressive symptoms.  Perhaps other variables such as perceived 
controllability or social support that were not specifically evaluated in this study may be utilized 
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more frequently by minority individuals.  These variables may offer a protective shield or buffer 
against psychological distress regardless of type of coping strategy utilized.   
Relationship between Coping and Depressive Symptoms 
 Emotion-focused coping was significantly associated with increased endorsement of 
depressive symptoms.  Specifically, participants who utilized confrontive, distancing, self-
controlling, escape-avoidance, and strategies that involved accepting responsibility for being 
HIV- positive reported increased depressive symptoms.  This suggests that individuals who 
respond to the stress associated with being HIV positive with increased hostility, avoidance, self-
blame, detachment, and strict regulation of thoughts or emotions may experience increased 
emotional distress and depressive symptoms.  Again, no protective benefits of problem-focused 
coping were noted to be significantly associated with decreased depressive symptoms.   
Substance Use and Coping 
 It was hypothesized that participants with a history of substance abuse would utilize 
emotion-focused coping strategies more than problem focused coping strategies.  Specifically, it 
was expected that participants with a history of substance abuse would utilize significantly more 
avoidant coping than participants who had no history of substance abuse.  In other populations, 
increased use of avoidant coping has been noted in individuals with a history of substance use 
(Avants, Warburton, & Margolin, 2000; Belding,et al., 1996).  However, the current results 
showed that individuals with a history of intravenous drug use utilized significantly more 
confrontive coping strategies.  These coping strategies include aggressive or hostile efforts to 
resolve a stressful situation.   
 The differences noted in the current study may reflect the use of different assessment 
instruments to evaluate coping strategies.  These differences may also be related to different 
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sampling procedures.  Much of the current literature regarding HIV and substance use has been 
conducted at outpatient substance abuse treatment centers. The current study consisted of 
primarily low-income participants who were receiving treatment at an ambulatory outpatient 
HIV clinic associated with a public teaching hospital.  It may be that these community samples 
are confronted with economical and cultural issues, such as living with community violence, that 
differs from participants in other research samples (Plummer & Slane, 1996).   Further research 
regarding the role of coping in individuals with substance abuse and subsequent impact on 
adherence behaviors is needed.  
Summary 
 The primary purpose of the current study was to evaluate the effects of initial coping 
strategies on long-term appointment attendance in individuals with HIV.  It was predicted that 
problem-focused coping would be associated with attending regularly scheduled clinic visits and 
emotion-focused coping would be predictive of failure to attend appointments.  Attendance 
information was retrospectively obtained by reviewing medical records.  Multiple regression 
analysis revealed that the coping style used by participants did not predict appointment 
attendance above and beyond the variance predicted by demographic, illness, and distress related 
factors.  However, minority status, depressive symptoms, and history of intravenous drug use did 
emerge as reliable predictors of failure to attend scheduled clinic appointments over a three-year 
follow-up period.  These data must be interpreted with caution because the sample included in 
the multiple regression bias was a subset of a smaller sample and is subject to selection bias.  
However, the strength of this data set is supported by the fact that no dignificant differences 
occurred between the total sample and regression sample and no evidence of range restriction 
was noted.  
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 Although further research confirming these results with a broader sample that does not 
represent such a large selection bias is needed, these results suggest that information that is easily 
obtained during the patient’s initial contact with the clinic may be critical in determining who is 
most at risk for failing to attend scheduled clinic appointments on a long-term basis.  Since, 
attendance at clinic appointments is necessary to receive appropriate HIV medical care and to 
ensure treatment success, identification of variables related to non-attendance is important.  
Further research should evaluate the specific variables associated with poor appointment 
attendance among minority individuals. 
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Appendix A 
Demographics Questionnaire 
Subject #:        Intake Date:    
DOB:        EKL#:     
Age:        Date of HIV Diagnosis:   
Sex:    Male     Female 
Race:  Caucasian  African American Hispanic Other:    
Income (yearly):   <$10,000 $10-20,000 $20-30,000 $30-40,000 >$40,000   
Education (Highest Grade Completed):    
Marital Status:  Single Married Divorced Widowed Other:    
Sexual Orientation: Homo/Bisexual Heterosexual 
Substance Use: 
 IV Drug Use:   Yes (current/past) No 
 IV Drug Use Partner Yes   No 
 Blood Recipient  Yes   No  What Year?   
 Other Drug Use in Last 6 Months 
  Marijuana Y   N Cocaine/Crack  Y  N  LSD/Acid  Y  N 
  Speed/Crystal Meth  Y  N Rush/Ethyl/Poppers  Y  N 
Tobacco Use Y  N      How Much Per Day?   
ETOH Consumption: Y  N    
 How Much?  <7 oz week  >7oz week Average Number (daily):   
Antiretroviral Medications: Y  N   Names:    Date Started:   
T-cell Counts: CD4   
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Appendix B 
Ways of Coping Questionnaire: Coping Subscales 
____________________________________________________________________ 
Coping Subscale    Description 
____________________________________________________________________ 
 
Confrontive Coping    Aggressive or hostile efforts to resolve 
the stressful situation 
 
 
Self-Controlling    Efforts to regulate thoughts, behaviors, 
or emotions 
 
Distancing     Cognitive efforts to detach from the 
stressful situation or minimize its impact 
 
Seeking Social Support   Efforts to find emotional, social, and 
educational support from others 
 
Accepting Responsibility   Recognizing personal role in the 
situation and attempts to correct any 
problems 
 
Escape-Avoidance    Cognitive and behavioral efforts to 
escape or avoid the stressful situation. 
 
Planful Problem Solving   Purposeful and well thought out efforts 
to solve the problem at hand 
 
Positive Reappraisal    Efforts to create positive meaning by 
focusing on positive aspects of stressful 
situation (e.g., chance for personal 
growth). Religious reappraisal is also 
included here. 
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Appendix C 
Symptom Checklist for HIV Infection 
1. Oral candidiasis (ever) 
2. Lymphadenopathy/thrush (by examination, currently) 
3. Nonallergic body rash (history of, during last three months) 
4. Shingles (history of, during last three months) 
5. Sinusitis (history of, during last three months) 
6. Oral leukoplakia (by examination, currently) 
7. Fever (history of, during last three months) 
8. Night sweats (history of, during last three months) 
9. Rashing or scaling around eyes (history of, during last three months) 
10. Diarrhea (history of, during last three months) 
11. Psoriasis (history of, during last three months) 
12. Shortness of breath (history of, during last three months) 
13. Easy bruising (history of, during last three months) 
14. Sore throat (history of, during last three months) 
15. Persistent cough (history of, during last three months) 
16. Meningitis (history of, during last three months) 
17. Hair loss (history of, during last three months) 
18. Pneumonia (history of, during last three months) 
19. Herpes (oral/genital) (ever) 
20. Weight loss (more than 10%) (history of, during last three months) 
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Appendix D 
Informed Consent 
Louisiana State University Medical Center in New Orleans 
1. Study Title: The impact of stress, mood, and social support on HIV disease status 
2. Performance Sites: Earl K. Long Medical Center, Baton Rouge, Louisiana. 
3. Names and Telephone Numbers of Investigators: 
    For 24-hour access, please call ….. (504) 358-1105 
    Phillip J. Brantley, Ph.D. …………(504) 358-1105 
    Glenn N. Jones, Ph.D. ……………(504) 358-1105 
    Jennifer McClure …………………(504) 358-1105 
    Sheryl Catz, M.A. ………………..(504) 358-3927    
 
4. Purpose of the Study: This is a research study designed to investigate how stress, mood, and 
social support impact the health status of patients with HIV (Human Immunodeficiency Virus). 
Aside from participating in a brief psychological/medical history and filling out questionnaires 
(e.g., on stress, HIV symptoms, mood, and social support) about every six months, research 
subjects will not be treated any differently than other patients at the clinic. The laboratory 
analysis of immune functioning is part of the medical assessment that all patients undergo 
routinely.  
 
5. Subject Inclusion Criteria: Individuals between the ages of 18 and 65 are eligible to 
participate in the study. Participants must be HIV positive. 
 
6. Subject Exclusion Criteria: Individuals will not be eligible to participate in the study if they 
are unable to read or comprehend the nature of the questionnaires for any reason (e.g., illiteracy). 
 
7. Description of the Study: During a routine clinic appointment, when laboratory analysis of 
immune functioning has been scheduled, patients at the clinic will be informed of the study by an 
attending nurse or physician. If a patient volunteers to participate, he/she will sign the informed 
consent. A graduate student in Clinical Psychology at Louisiana State University will conduct an 
interview to gather a brief medical and psychological history. Subjects then will complete 
questionnaires (e.g., on stressful life events, social support, mood, coping, and HIV symptoms).  
Subjects allow the experimenter access to their medical records to obtain laboratory reports and 
other medical information (e.g., medication usage, onset of symptoms, number of visits to the 
clinic).  At or before regularly scheduled follow-up clinic appointments, participants will be 
reminded of the project and again asked to complete the questionnaires.  
 
8. Benefits to Subject: Subjects will receive $5.00 following each participation in the study. 
Other potential benefits may include increased knowledge about HIV and strategies to cope with 
the disease. 
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9. Risks to Subject: There are no known major physical, psychological, or social risks 
associated with participation in the study. However, there may be unforeseen risks associated 
with participation. Lesser risks can be explained if the subjects desire this information. Subjects 
should not expect their medical conditions to improve by participation in this study. If the 
subjects wish, the experimenter can provide a referral for additional assistance. 
 
10. Alternatives to Participation in the Study: Participation is voluntary. Subjects who choose 
not to participate will attend their clinic appointments as usual.   
 
11. Subject Removal: There are no foreseeable circumstances under which eligible subjects 
would be removed from the study against their wishes. Subjects who fail to return for their 
regularly scheduled clinic appointments (e.g., for over a year) may be removed from the study. 
 
12. Subject’s Right to Refuse to Participate or Withdraw: Study subjects may refuse to 
participate or withdraw from the study at any time without jeopardizing, in any way, their 
medical treatment at this institution in the present or the future.  Should significant new findings 
develop during the course of the research which may relate to the subject’s willingness to 
continue participation, that information will be provided to the subject.  
 
13. Subject’s Right to Privacy: The results of the study may be published, released to a funding 
agency or presented in a scholarly fashion (e.g., at a conference). The privacy and confidentiality 
of subjects will be protected, and they will not be identified in any way.  
 
14. Release of Information: The medical records related to the study are available to the 
experimenter.  By agreeing to participate in this research study and by signing the consent form, 
the subject gives permission for his/her attending medical staff to release relevant medical 
information (e.g., diagnoses, medications, rate of clinic attendance) to the experimenter.  
 
15. Financial Information: A) Participation in this study will not result in any extra charges 
above and beyond those routinely incurred by patients with similar illnesses. B) The costs of 
study related and unforeseen complications must be met by subjects. C) Subject Payment: 
Subjects will be paid $5.00 for participation in the study. 
 
16. Signatures: The study has been discussed with me and all my questions have been answered.  
I understand that additional questions regarding the study should be directed to investigators 
listed on page 1 of this consent form. I understand that if I have questions about subjects’ rights, 
or other concerns, I can contact Dr. Perry, G. Rigby, Chancellor, at (504) 568-4801. I agree with 
the terms above and acknowledge I have been given a copy of the consent form. 
 
 
_______________________________________________             _________ 
Signature of Subject                 Date 
 
 
______________________________________________             _________ 
Signature of Witness                 Date 
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